



KINEXUS

Kinexus Announces the Release of New Cell Cycle Screen

New Kinetworks™ Screen tracks 30 proteins involved in cell growth and proliferation

FOR IMMEDIATE RELEASE MARCH 11, 2003

VANCOUVER, British Columbia - Kinexus Bioinformatics Corporation is pleased to announce the release of a new proteomics signal transduction protein profiling service that tracks proteins involved in cell growth and proliferation. The Kinetworks™ Cell Cycle Screen, or KCCP-1.0, which uses only validated antibodies, is a cost effective solution for researchers to detect up to 30 cell cycle proteins in their model system with high reproducibility, accuracy, and speed. Research in understanding cell cycle control has many implications for the development of therapeutics for diseases such as cancer, which involves uncontrolled cell growth.

Kinexus also offers screening services for the detection of 75 protein kinases, 33 phosphoproteins, 25 phosphatases, 25 apoptosis and 25 stress/heat shock proteins using as little as 300 ug of total cell or tissue lysate protein. These screening services have many applications including the identification of drug targets, disease diagnostic markers or new research leads, characterization of drug candidates for mechanisms of action and toxicity; and validation of animal models for testing drug leads to treated human diseases. Sample preparation instructions, service agreements and order forms are available online at www.kinexus.ca.

“By adopting a systems biology approach, our Kinetworks™ multi-immunoblotting service has proven instrumental in uncovering changes in important signaling proteins in several experimental model systems and disease states” said Dr. Steven Pelech, President and Chief Scientific Officer of Kinexus, and a Professor of Medicine at the University of British Columbia. “The results from our Kinetworks™ screening services have resulted in many publications, with the most recent one in the Journal of Biological Chemistry describing how our Kinetworks™ proteomics technology identified the protein kinase JNK as a potential drug target for treatment of some forms of colon cancer and other solid tumors.”

Kinexus Bioinformatics Corporation is a private, biopharmaceutical company engaged in the development of innovative methods to establish the relationships of signaling proteins within cellular communication networks. The application of this knowledge strategically positions Kinexus and its clients to advance drug development, rational drug design, disease diagnosis and personalized therapies to improve human health.

For further information, please contact Kinexus Bioinformatics Corporation toll free at 1-866-KINEXUS or visit our website at www.kinexus.ca.

PRESS RELEASE - 2003 MARCH 11